Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...

At the American Society of Cell and Gene Therapy conference, there were questions and qualms on how Vinay Prasad may change ...

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...

A hot (if cautious) topic at the big gene therapy meeting: what Vinay Prasad's appointment might mean for approvals in rare ...

For a brief period in 2022, Dr. Vinay Prasad faked a concern about routine vaccines to infect unvaccinated children with ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...

From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...

Vinay Prasad, a skeptic of mainstream medicine, is now a top FDA official. Change is coming for some drugmakers, one way or ...

The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...